Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EUTHROID-1 vs EUTHYROX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Euthroid-1 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones that replace endogenous thyroid hormone. T4 is converted to T3 in peripheral tissues, acting on thyroid hormone receptors to regulate gene transcription, metabolism, and growth.
Synthetic levothyroxine is a T4 hormone that is converted to T3, binding to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate, cardiac output, and thermogenesis.
Hypothyroidism, primary, secondary, or tertiary,Thyroid-stimulating hormone suppression in thyroid cancer (off-label)
Hypothyroidism (primary, secondary, tertiary),Thyroid-stimulating hormone (TSH) suppression in thyroid cancer,Thyroid hormone replacement therapy in myxedema coma,Off-label: Subclinical hypothyroidism (when TSH >10 m IU/L or with symptoms)
One tablet orally once daily, typically in the morning on an empty stomach. Contains 100 mcg levothyroxine and 25 mcg liothyronine.
Initial adult dose 25-50 mcg orally once daily; titrate by 12.5-25 mcg increments every 4-6 weeks; maintenance dose typically 100-200 mcg daily.
Terminal elimination half-life: approximately 5-7 days for levothyroxine (T4) and 2-4 days for liothyronine (T3). Clinical context: Steady-state achieved in 6-8 weeks; half-life prolonged in hypothyroidism, shortened in hyperthyroidism.
Terminal half-life: 6-7 days in euthyroid individuals. Longer in hypothyroidism (9-10 days) and shorter in hyperthyroidism (3-4 days). Clinically, steady-state achieved in 4-6 weeks.
Levothyroxine is deiodinated to liothyronine in peripheral tissues via iodothyronine deiodinases (DIO1, DIO2). Liothyronine undergoes deiodination and conjugation (glucuronidation, sulfation) in liver.
Partially deiodinated to active T3 and inactive reverse T3 (r T3) in liver, kidney, and other tissues. Conjugation with glucuronides and sulfates. Minimal CYP450 involvement.
Renal: ~20-40% as unchanged drug; biliary/fecal: ~40-60% as metabolites and conjugates; total clearance is primarily hepatic.
Primarily renal (approximately 40-50% as unchanged drug and metabolites), with about 20% fecal elimination via bile. Minor biliary excretion.
>99% bound; T4 bound to thyroxine-binding globulin (TBG: ~70%), transthyretin (10-15%), and albumin (15-20%); T3 binds less avidly to TBG and albumin.
>99.9% bound to thyroxine-binding globulin (TBG), transthyretin (TTR), and albumin. Lewothyroxine is the active form.
Vd: approximately 0.1-0.2 L/kg for T4; 0.3-0.5 L/kg for T3; reflects distribution primarily into extracellular fluid and limited tissue penetration for T4, wider distribution for T3.
0.10-0.15 L/kg, reflecting distribution primarily into extracellular fluid and tissues with high affinity binding to thyroid hormone receptors.
Oral: 50-80% for T4 (absorption depends on formulation and food); T3 nearly completely absorbed (>90%).
Oral: 50-80% (variable, influenced by food, GI disease, and formulation). IV: 100%.
No specific GFR-based dose adjustment required; however, in severe renal failure, monitor thyroid function closely as drug clearance may be altered.
No renal adjustment required as levothyroxine is primarily metabolized and excreted in feces. Monitor TSH and free T4 in patients with severe renal impairment.
No specific Child-Pugh based dose adjustment; caution in severe hepatic impairment due to altered metabolism of thyroid hormones.
No specific Child-Pugh adjustment; however, severe hepatic impairment may reduce T4 to T3 conversion; monitor thyroid function tests.
Weight-based dosing for hypothyroidism: initial 12.5-25 mcg levothyroxine equivalent per day, adjusted based on TSH and free T4 levels. Not recommended for children due to fixed combination ratio.
Weight-based: 0-3 months: 10-15 mcg/kg/day; 3-6 months: 8-10 mcg/kg/day; 6-12 months: 6-8 mcg/kg/day; 1-5 years: 5-6 mcg/kg/day; 6-12 years: 4-5 mcg/kg/day; >12 years: 2-3 mcg/kg/day. Administer orally once daily.
Start with lower dose (e.g., half tablet) and titrate slowly; monitor for cardiac side effects due to increased sensitivity to thyroid hormones.
Elderly patients (especially >65 years) or those with cardiovascular disease: start at 12.5-25 mcg orally once daily; increase by 12.5 mcg every 4-6 weeks; lower maintenance doses often required.
No black box warning.
Not approved for weight loss. Doses above physiologic requirements may produce serious or life-threatening toxicity, especially when used with sympathomimetic amines.
Cardiovascular toxicity with overdosage; may exacerbate angina, arrhythmias, hypertension. Caution in patients with diabetes mellitus (may increase blood glucose) and adrenal insufficiency. Monitor thyroid function tests and adjust dose.
Cardiovascular effects (angina, arrhythmias, hypertension) in patients with underlying heart disease. Risk of thyrotoxic crisis if dose is excessive. Adrenal insufficiency: adjust corticosteroid dose before starting in patients with adrenal insufficiency. Diabetes mellitus: may increase blood glucose and require adjustment of antidiabetic therapy. Osteoporosis: chronic TSH suppression increases risk of bone loss. Interactions with anticoagulants (warfarin), antidiabetic agents, and SSRIs. Discontinue use for weight loss due to serious toxicity.
Untreated adrenal insufficiency, untreated thyrotoxicosis, acute myocardial infarction, hypersensitivity to any component.
Untreated adrenal insufficiency, untreated thyrotoxicosis, acute myocardial infarction, hypersensitivity to any component.
Avoid high-fiber foods, grapefruit juice, and soy products within 4 hours of taking Euthyroid-1 as they may interfere with absorption. Maintain consistent iodine intake; avoid drastic increases in cruciferous vegetables (e.g., broccoli, kale) without medical advice. Calcium-fortified foods and iron-rich foods should be separated by at least 4 hours.
Levothyroxine absorption is decreased by high-fiber foods (e.g., bran, whole grains), soy products, grapefruit juice, walnuts, and cottonseed meal. Also, calcium-fortified foods and beverages can reduce absorption. Take levothyroxine at least 4 hours apart from these foods. Avoid concomitant ingestion with coffee or milk; if needed, maintain consistency. Caffeine may slightly reduce absorption.
EUTHROID-1 (levothyroxine) is a thyroid hormone replacement. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, fetal neurodevelopmental deficits, preterm delivery, and low birth weight. Levothyroxine itself is not teratogenic; the FDA pregnancy category is A. No increased risk of congenital malformations has been reported with therapeutic doses. In the first trimester, adequate maternal T4 is critical for fetal brain development. In the second and third trimesters, placental transfer of levothyroxine is minimal as fetal thyroid function matures. Untreated hyperthyroidism from over-replacement may increase risk of fetal tachycardia, growth restriction, and preterm birth.
EUTHYROX (levothyroxine) is a thyroid hormone replacement. Maternal hypothyroidism itself carries significant risks to the fetus, including neurodevelopmental deficits, preterm birth, and low birth weight. The drug does not cross the placenta significantly; fetal thyroid function is independent. No known teratogenic effects from levothyroxine at therapeutic doses. First trimester: essential for maternal euthyroidism to prevent fetal neurodevelopmental impairment. Second and third trimesters: maintenance of maternal euthyroidism supports normal fetal growth and development. Insufficient treatment increases risks.
Levothyroxine is excreted into breast milk in low amounts. The milk-to-plasma (M/P) ratio is approximately 0.5. The estimated daily infant dose through breast milk is less than 1% of the maternal dose, which is negligible. No adverse effects in infants have been reported. The American Academy of Pediatrics considers levothyroxine compatible with breastfeeding. Monitoring of infant thyroid function is not routinely required but may be considered if maternal dose is high.
Levothyroxine is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.5. It is generally considered compatible with breastfeeding at therapeutic doses as it does not pose a risk to the infant. Monitoring infant thyroid function is not routinely required unless maternal dose is very high or infant shows symptoms.
Pregnancy increases total body water, plasma volume, and renal clearance, and alters thyroid-binding globulin synthesis, leading to increased levothyroxine requirements. Dose adjustments are often needed as early as 4-6 weeks gestation. Typically, the dose is increased by 30-50% from preconception baseline. For patients already on levothyroxine, increase dose by 2 additional tablets per week (e.g., 2 extra doses) or approximately 30% upon confirmation of pregnancy. Monitor TSH every 4-6 weeks and adjust to maintain TSH <2.5 m IU/L in the first trimester and <3.0 m IU/L in later trimesters. After delivery, reduce dose to prepregnancy level and check TSH 6 weeks postpartum.
Pregnancy increases thyroid-binding globulin and plasma volume, leading to increased levothyroxine requirements. Dose often increases by 30-50% during pregnancy, starting as early as 4-6 weeks gestation. Frequent monitoring (every 4 weeks) and dose adjustments are necessary to maintain TSH in trimester-specific ranges: first trimester 0.1-2.5 m IU/L, second trimester 0.2-3.0 m IU/L, third trimester 0.3-3.0 m IU/L. Postpartum dose should be reduced to pre-pregnancy levels.
Euthyroid-1 contains levothyroxine (T4) and liothyronine (T3) in a fixed 4:1 ratio. Monitor TSH, free T4, and free T3 levels to avoid overtreatment, especially due to T3 component. Use with caution in elderly and patients with cardiovascular disease; start with lower doses. T3 has a shorter half-life (about 1 day) vs T4 (7 days); consider this when interpreting labs. Drug interactions: iron, calcium, antacids, and bile acid sequestrants may reduce absorption; separate by at least 4 hours.
Levothyroxine (EUTHYROX) is the standard therapy for hypothyroidism. Absorption is reduced by calcium, iron, soy, and fiber; take on an empty stomach 30-60 minutes before breakfast. Dose adjustments needed in pregnancy, weight changes, and with interacting drugs (e.g., estrogens, rifampin, phenytoin). Monitor TSH 6-8 weeks after dose change. In hyperthyroidism, rapid levothyroxine withdrawal can precipitate thyroid storm; taper cautiously. For myxedema coma, use IV levothyroxine (not oral). When switching from a T3-containing preparation, cross-titration is required.
Take exactly as prescribed at the same time each day, usually in the morning on an empty stomach with water.,Do not stop or change dose without consulting your doctor; symptoms may take weeks to improve.,Inform your doctor of all other medications and supplements you take, especially iron, calcium, and antacids.,Report symptoms of hyperthyroidism (rapid heart rate, chest pain, sweating) or hypothyroidism (fatigue, weight gain, cold intolerance).,Store at room temperature away from moisture and heat; keep out of reach of children.
Take levothyroxine exactly as prescribed, at the same time each day.,Take on an empty stomach, at least 30-60 minutes before breakfast or any food.,Do not take with calcium supplements, iron supplements, antacids, or high-fiber foods; separate by at least 4 hours.,Do not stop or change dose without consulting your doctor.,If you miss a dose, take it as soon as you remember, but skip if it is almost time for the next dose; do not double dose.,Report symptoms of hyperthyroidism (rapid heart rate, palpitations, anxiety, weight loss) or hypothyroidism (fatigue, weight gain, cold intolerance).,Blood tests (TSH) will be done regularly to monitor dose.,Tell your doctor if you are pregnant, planning pregnancy, or breastfeeding.,Keep all medications out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EUTHROID-1 vs EUTHYROX, answered by our medical review team.
EUTHROID-1 is a Thyroid Hormone Replacement that works by Euthroid-1 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones that replace endogenous thyroid hormone. T4 is converted to T3 in peripheral tissues, acting on thyroid hormone receptors to regulate gene transcription, metabolism, and growth.. EUTHYROX is a Thyroid Hormone Replacement that works by Synthetic levothyroxine is a T4 hormone that is converted to T3, binding to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate, cardiac output, and thermogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EUTHROID-1 and EUTHYROX depend on the specific clinical indication. These are both Thyroid Hormone Replacement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EUTHROID-1 is: One tablet orally once daily, typically in the morning on an empty stomach. Contains 100 mcg levothyroxine and 25 mcg liothyronine.. The standard adult dose of EUTHYROX is: Initial adult dose 25-50 mcg orally once daily; titrate by 12.5-25 mcg increments every 4-6 weeks; maintenance dose typically 100-200 mcg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EUTHROID-1 and EUTHYROX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EUTHROID-1 is classified as Category C. EUTHROID-1 (levothyroxine) is a thyroid hormone replacement. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, fetal neurodevelopmental deficits,. EUTHYROX is classified as Category C. EUTHYROX (levothyroxine) is a thyroid hormone replacement. Maternal hypothyroidism itself carries significant risks to the fetus, including neurodevelopmental deficits, preterm bir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.